Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents-Reference-Cited by-同舟云学术

Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents

Published:2023-08-08 Issue:11 Volume:64 Page:1840-1846
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Scamuffa Maria Cristina¹,Latagliata Roberto²,Carmosino Ida¹,Di Veroli Ambra²,Scalzulli Emilia¹,Trapè Giulio²,Ciotti Giulia¹,De Angelis Gioia²,Tartaglia Germana¹,Tarnani Michela²,Breccia Massimo¹,Girmenia Corrado¹

Affiliation:

1. Hematology, Department of Translational and Precision Medicine, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

2. Hematology, Belcolle Hospital, Viterbo, Italy

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2239407

Reference19 articles.

1. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions

2. Current treatment algorithm for the management of lower-risk MDS

3. Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis

4. Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management

5. Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)